| 摘要 |
PURPOSE: To obtain a pharmaceutical composition containing lithium salt facilitating transfer of a poly(unsaturated fatty acid) (PUFA) and/or lithium from an aqueous phase to fat phase, accelerating the incorporation thereof and providing a medicine having heightened treatment efficiency by including a lithium salt of the PUFA. CONSTITUTION: This pharmaceutical composition includes a lithium salt of a 18-22C PUFA (e.g. γ-linolenic acid and linoleic acid) having at least two unsaturated C-C bonds with a physiologically permissible vehicle or carrier material. Further, a gastic fluid resistant and release delaying coating is applied on the lithium salt when the lithium salt is a solid medicine applied to the stomach for a treatment for Alzheimer's disease by an oral dose. A transfer of the lithium salt to a lipid circumstance, which is difficult by a conventional lithium salt used in a lithium treatment, is accelerated, and thereby such a large amount of the lithium ion as to be achieved only by administering an impermissible poisonous amount of the lithium salt can be sent to a specific portion. |
